Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel VIVORYON THERAPEUTICS N.V. AEX:VVY.NL, NL00150002Q7

  • 0,720 23 apr 2024 17:35
  • +0,150 (+26,32%) Dagrange 0,613 - 0,825
  • 2.581.230 Gem. (3M) 632,4K

Vivoryon is de naam. Daarom nieuw draadje

6.265 Posts
Pagina: «« 1 ... 107 108 109 110 111 ... 314 »» | Laatste | Omlaag ↓
  1. Amarillo 31 augustus 2020 09:55
    Ff wat serieus nieuws van de concurrentie mensen: Neuralink van Elon Musk heeft een chip geimplanterrd in het brein van een varken om zo hersenaandoeningen te kunnen bestrijden waaronder ook Altzheimer..zit ook hier in de testfase en nog bij een varken..oke,oke..maar die moeten we ook ff niet uitvlakken vind in
  2. forum rang 4 K. Wiebes 31 augustus 2020 14:39
    Reactie van Gretchen (dat rood moet je er zelf maar even bij verzinnen):

    Dear K. Wiebes,

    Please see below a transcript of your questions from our call on Friday and the replies
    in dark red from Vivoryon. Please contact me with any further questions.

    “Being that dissenting shareholders would receive €9.00 for their shares, wouldn’t a
    large proportion of shareholders prefer that option since the shares are trading
    significantly below €9?”

    --If shareholders holding more than 2% of the voting rights in the aggregate have an
    objection recorded in the shareholders’ meeting, the conversion and thus the
    compensation offer will not be implemented.
    Therefore, if too many shareholders try to use this proposal as an exit option, no
    compensation will be paid.

    “For example, MorphoSys has sold some of their position and they still own 10%
    of the shares, therefore they would welcome the chance to liquidate their shares
    for the €9.”

    --Again, if they would dissent at such a level (i.e. more than 2%), there is no way
    the transaction goes through and thus, no compensation would be paid.
    Therefore, the compensation offer does not present an exit option, in particular
    not for major shareholders.

    “Is the management therefore convinced that MorphoSys would not dissent
    to the transaction?”

    -- No major shareholder has agreed to the transaction in advance. However,
    given the advantages for the company and its shareholders of the proposed
    N.V. structure, the management believes that all major shareholders will vote
    in favour of the proposed resolution. The legal form of an N.V. would reduce
    administrative efforts for both the Company and its shareholders, would
    facilitate the access to a broader investor base including in the U.S.

    “Since the company requested a valuation analysis to come to the € 8.87 fair
    value of the shares, can Vivoryon please post that analysis report on the website?”

    -- The valuation report is part of the conversion report and will be published
    together with the invitation and the other documents relating to the General
    Meeting on or around 3 September 2020.

    Best regards,
    Gretchen

    Gretchen L.P. Schweitzer
    Managing Director
    Trophic | Communications GmbH

    Nog even een vraag teruggestuurd:
    Het voorstel moet dus met 98% van de stemmen worden aangenomen?
  3. forum rang 10 DeZwarteRidder 31 augustus 2020 14:42
    quote:

    K. Wiebes schreef op 31 augustus 2020 14:39:

    Reactie van Gretchen (dat rood moet je er zelf maar even bij verzinnen):

    Dear K. Wiebes,

    Please see below a transcript of your questions from our call on Friday and the replies in dark red from
    Vivoryon. Please contact me with any further questions.

    “Being that dissenting shareholders would receive €9.00 for their shares, wouldn’t a large proportion of
    shareholders prefer that option since the shares are trading significantly below €9?”

    --If shareholders holding more than 2% of the voting rights in the aggregate have an objection recorded
    in the shareholders’ meeting, the conversion and thus the compensation offer will not be implemented.
    Therefore, if too many shareholders try to use this proposal as an exit option, no compensation will be
    paid.

    “For example, MorphoSys has sold some of their position and they still own 10% of the shares, therefore
    they would welcome the chance to liquidate their shares for the €9.”

    --Again, if they would dissent at such a level (i.e. more than 2%), there is no way the transaction goes
    through and thus, no compensation would be paid. Therefore, the compensation offer does not present
    an exit option, in particular not for major shareholders.

    “Is the management therefore convinced that MorphoSys would not dissent to the transaction?”

    -- No major shareholder has agreed to the transaction in advance. However, given the advantages
    for the company and its shareholders of the proposed N.V. structure, the management believes that
    all major shareholders will vote in favour of the proposed resolution. The legal form of an N.V. would
    reduce administrative efforts for both the Company and its shareholders, would facilitate the access
    to a broader investor base including in the U.S.

    “Since the company requested a valuation analysis to come to the € 8.87 fair value of the shares,
    can Vivoryon please post that analysis report on the website?”

    -- The valuation report is part of the conversion report and will be published together with the
    invitation and the other documents relating to the General Meeting on or around 3 September
    2020.
    Best regards,
    Gretchen
    Gretchen L.P. Schweitzer
    Managing Director
    Trophic | Communications GmbH
    Nog even een vraag teruggestuurd:
    Het voorstel moet dus met 98% van de stemmen worden aangenomen?
    Weet je het nou nog niet.....????
  4. forum rang 4 K. Wiebes 1 september 2020 14:17
    Dear K. Wiebes,

    Please see the answers from Vivoryon to your questions below in red.

    - So the proposal will need 98% of the votes?
    As per German law, to be ratified the proposal will need a majority of 75% of
    the votes cast at the AGM, however, the proposal will not be implemented if
    for more than 2% in total of the overall voting rights (i.e. more than 399,509
    shares) objections are recorded in the minutes of the meeting.

    - And if not: how much money is Viv. willing to spend on compensation?
    The maximum compensation would correspond to a maximum of 2% of the
    shares (out of 19,975,482) at a compensation amount of EUR 9 per share.
    Details will be published on September 3rd on the company’s webpage.

    Should there be additional questions, please let me know.

    Best,
    Gretchen
  5. forum rang 4 Kuiken 3 september 2020 19:02
    VIVO heeft onderneming laten waarderen door een Zwitsers bedrijf Venture Valuation( oa gefinancierd door Novartis en European Investment Bank) Het bedrijf is actief in de bio/pharma hoek.
    Het rapport doorgelezen en conclusie:

    Ze zien een beperkte kans van slagen van VIVO. Percentages tussen de 2,7 en 11% voor de twee hoofd pipeline-producten.
    Kans van slagen neemt toe naarmate Phase II overgaat naar III en naar approval.
    Tijdstip van implementatie 2027/2029, maar mochten er traject-versnellingen worden afgegeven
    vanwege gunstige onderzoeksresultaten, kan dat ook eerde worden.
    Het is zeker geen Hosanna-rapport Onderzoekers zien veel beren op de weg.
    Maar na vergelijking met vele gelijksoortige ondernemingen en ook het afwegen van de concurrentie, geven ze VIVO TWEE,
    keer de waarde mee van wat er nu op de koersborden staat.

    beetje doorklikken op VIVO-site en u kunt het zelf lezen.
6.265 Posts
Pagina: «« 1 ... 107 108 109 110 111 ... 314 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links